232 related articles for article (PubMed ID: 31492829)
1. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab.
Harsch IA; Konturek PC
Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829
[TBL] [Abstract][Full Text] [Related]
2. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
[TBL] [Abstract][Full Text] [Related]
3. Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody.
Sato K; Onuma E; Yocum RC; Ogata E
Semin Oncol; 2003 Oct; 30(5 Suppl 16):167-73. PubMed ID: 14613038
[TBL] [Abstract][Full Text] [Related]
4. PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab.
Salahudeen AA; Gupta A; Jones JC; Cowan RW; Vusirikala M; Kwong C; Naina HV
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):e137-40. PubMed ID: 26187654
[No Abstract] [Full Text] [Related]
5. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
6. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
7. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
8. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
9. Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.
Teng J; Abell S; Hicks RJ; Hofman MS; Sachithanandan N; McKelvie P; MacIsaac RJ
Clin Endocrinol (Oxf); 2014 Dec; 81(6):940-2. PubMed ID: 24890549
[No Abstract] [Full Text] [Related]
10. Neuroendocrine Carcinoma as a Cause of Humoral Hypercalcemia of Malignancy: A Case of a Patient With Elevated Parathyroid Hormone-Related Protein.
Christensen BR; Rendo MJ; Beeler BW; Huddleston BJ; Fenderson JL
Cureus; 2022 Mar; 14(3):e23398. PubMed ID: 35481321
[TBL] [Abstract][Full Text] [Related]
11. Malignant hypercalcemia in vulvar cancer.
Bilenchi R; Poggiali S; Pisani C; Santopietro R; Miracco C; Vatti R; Lucani B; Andreassi A; Gonnelli S
Minerva Ginecol; 2005 Oct; 57(5):569-74. PubMed ID: 16205603
[TBL] [Abstract][Full Text] [Related]
12. Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature.
Nakajima K; Tamai M; Okaniwa S; Nakamura Y; Kobayashi M; Niwa T; Horigome N; Ito N; Suzuki S; Nishio S; Komatsu M
Endocr J; 2013; 60(5):557-62. PubMed ID: 23303131
[TBL] [Abstract][Full Text] [Related]
13. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
[TBL] [Abstract][Full Text] [Related]
14. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
15. Humoral hypercalcemia of malignancy with elevated plasma PTHrP, TNF alpha and IL-6 in cutaneous squamous cell carcinoma.
Mori H; Aoki K; Katayama I; Nishioka K; Umeda T
J Dermatol; 1996 Jul; 23(7):460-2. PubMed ID: 8772024
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of malignancy associated hypercalcemia].
Tai N; Inoue D
Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
[TBL] [Abstract][Full Text] [Related]
17. Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.
Roukain A; Alwan H; Bongiovanni M; Sykiotis GP; Kopp PA
Front Endocrinol (Lausanne); 2021; 12():794988. PubMed ID: 35173680
[TBL] [Abstract][Full Text] [Related]
18. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
[No Abstract] [Full Text] [Related]
19. Case report: cholangiocarcinoma and hypercalcemia.
Davis JM; Sadasivan R; Dwyer T; Van Veldhuizen P
Am J Med Sci; 1994 May; 307(5):350-2. PubMed ID: 8172229
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]